| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.81▲ | 0.81▲ | 0.81▲ | 0.82▼ | 0.89▼ |
| MA10 | 0.80▲ | 0.81▲ | 0.81▲ | 0.84▼ | 0.91▼ |
| MA20 | 0.81▲ | 0.82▲ | 0.82▼ | 0.90▼ | 0.86▼ |
| MA50 | 0.82▼ | 0.82▼ | 0.83▼ | 0.90▼ | 0.85▼ |
| MA100 | 0.82▼ | 0.85▼ | 0.87▼ | 0.86▼ | 1.07▼ |
| MA200 | 0.84▼ | 0.91▼ | 0.95▼ | 0.82▼ | 0.99▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.001▼ | 0.000▼ | -0.012▼ | 0.000▲ |
| RSI | 55.175▲ | 50.784▲ | 48.802▼ | 36.598▼ | 45.697▼ |
| STOCH | 60.497 | 22.740 | 21.867 | 21.132 | 30.153 |
| WILL %R | 0.000▲ | -30.867 | -52.373 | -81.282▼ | -85.323▼ |
| CCI | 224.459▲ | 36.970 | 4.723 | -92.762 | -36.374 |
|
Tuesday, October 14, 2025 10:00 PM
SEATTLE, Oct. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer ...
|
|
Monday, October 13, 2025 05:00 PM
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, ...
|
|
Sunday, October 12, 2025 10:00 PM
Portfolio covers high-purity Z-endoxifen enteric formulations, performance characteristics, and manufacturing methods, part of Atossa's multi-jurisdiction IP strategy to support clinical and ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/11/25 | 0.8277 | 0.8462 | 0.7912 | 0.8133 | 623,125 |
| 11/11/25 | 0.84 | 0.85 | 0.81 | 0.8277 | 236,223 |
| 10/11/25 | 0.83 | 0.8787 | 0.83 | 0.8378 | 478,248 |
| 07/11/25 | 0.80 | 0.83 | 0.78 | 0.8205 | 881,359 |
| 06/11/25 | 0.83 | 0.8432 | 0.8113 | 0.8145 | 327,014 |
| 05/11/25 | 0.84 | 0.848 | 0.825 | 0.8275 | 365,120 |
| 04/11/25 | 0.8556 | 0.889 | 0.8401 | 0.8481 | 605,360 |
| 03/11/25 | 0.90 | 0.907 | 0.8534 | 0.8633 | 533,652 |
| 31/10/25 | 0.873 | 0.909 | 0.87 | 0.8896 | 444,513 |
| 30/10/25 | 0.865 | 0.897 | 0.86 | 0.88 | 556,490 |
|
|
||||
|
|
||||
|
|